Early detection of cancer is vital for successful treatment and cure. Late detection invariable leads to intensive and toxic treatments, high treatment costs and treatment failure. Trucheck, brought to you in South Africa by Unique Diagnostics, is a revolutionary test, based on a simple blood draw, for early detection of multiple types of cancer to help secure you and your family's future.
Cancer is a ticking time bomb globally. Every year about 18 million women and men are diagnosed with various cancers including carcinomas, sarcomas, neuroendocrine tumors, melanomas. These cancers are also associated with about 9 million deaths. This translates into roughly 34 cancer cases being detected and 18 cancer related deaths every minute. Annually, these cancers contribute to:
~4.1 million newly diagnosed cases and 1.8 million deaths in Europe (including the UK).
~2.1 million newly diagnosed cases and 550,000 deaths in the US.
~1.2 million newly diagnosed cases and 760,000 deaths in India.
Due to changes in lifestyle as well as other risk factors, these numbers are stated to increase in the future. Detecting cancer early is vital to saving lives. Studies have shown that early detection of cancer improves survival rates.
Trucheck™ is a blood test that can enable early detection of multiple cancers in asymptomatic individuals.
Screening programmes are effective for some but not all cancer types and in general are far more complex and resource-intensive than early diagnosis as they require special equipment and dedicated personnel. Getting screening tests regularly may find breast, cervical, and colorectal (colon) cancers early, when treatment is likely to work best. Patient selection for screening programmes is based on age and risk factors to avoid excessive false positive studies.
Trucheck™ is a blood test that can enable early detection of multiple cancers in asymptomatic individuals. Trucheck™ is intended to be performed annually as a routine test.
Being a non-invasive blood-based test, Trucheck™ can minimize the need to visit a healthcare centre.
Advantages to the individuals:
1. Wait times for appointments are reduced
2. May be assimilated into annual health check-up
3. No risk of radiation or those associated with invasive procedures
Advantages to the system:
1. Reductions in avoidable / non-critical appointments
2. Minimizes procedures that may be retrospectively deemed unnecessary
3. Supports decision making in conjunction with existing tests / methods
Circulating Tumor Cells (CTCs) and their clusters are present in the blood of almost all cancer patients and are undetectable even in seemingly healthy individuals.
Trucheck™ technology to detect and characterise CTCs has been proven through extensive clinical validations involving more than 40,000 participants.
The test is a paradigm shift in cancer screening, as it does not involve radiation or invasive procedures. The test is performed at our world-class laboratory, which meets and exceeds all national and international standards.
Melanoma, Head and Neck, Salivary Gland, Thyroid, Lung, Breast, Liver, Biliary Tract, Gastro-Intestinal, Soft Tissue and Osteosarcomas, Mesothelioma, Urinary Tract, Gynaecological, Male Cancers including Prostate, CNS, Thymus, Adrenal, Skin.
Early detection of cancer is vital for successful treatment and cure. Late detection invariable leads to intensive and toxic treatments, high treatment costs and treatment failure.
Trucheck™ - Breast has an overall accuracy of > 99%.
Prostate Cancer affects more than 1.5 million men annually. More than 375,000 men die of Prostate Cancer each year.
Studies have shown that early detection of Prostate Cancer drastically improves survival rates. Trucheck™ - Prostate is a non-invasive diagnostic blood test that can enable early detection of Prostate Cancer in asymptomatic individuals.
Trucheck™ - Prostate is totally non-invasive, radiation free and can be availed from the comfort of your office or home. Trucheck™ - Prostate is intended to be performed annually as a routine test.
Trucheck™ - Prostate has overall accuracy > 99%.
Individuals with diabetes are at a higher risk of certain aggressive types of cancers such as the Liver, Gallbladder, Pancreas, Kidney, Bladder and Colon.
Early detection of these cancers is vital for successful treatment and cure. Trucheck - Diabetes is a revolutionary test, based on a simple blood draw, for early detection of 6 types of cancer whose risk is elevated in diabetic patients.
Trucheck™ - Diabetes has been clinically proven to have accuracy of > 99% in detecting these cancers early.